Biosynex (ALBIO.PA) Stock Price

Biosynex Price

Euronext·CLOSED
0.90EUR-0.0020 (-0.22 %)
Market closed

Revenue has compounded at 46.9% per year over the past 18 years to 101.17 M EUR. Earnings per share have grown at 115.0% per year over the last 5 years. Biosynex's net margin stands at -42.8%, down from 20.4% several years earlier. Biosynex currently offers a dividend yield of about 221.24%. The payout ratio is around 132% of earnings. Analysts set a median price target of 12.85 EUR, implying 1,321.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 90% above its 52-week low.

Biosynex stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biosynex over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biosynex stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biosynex's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biosynex Stock Price History
DateBiosynex Price
8/7/20260.90 EUR
8/6/20260.91 EUR
8/5/20260.90 EUR
8/4/20260.91 EUR
7/31/20260.92 EUR
7/30/20260.90 EUR
7/29/20260.91 EUR
7/28/20260.92 EUR
7/27/20260.94 EUR
7/24/20260.92 EUR
7/23/20260.93 EUR
7/22/20260.94 EUR
7/21/20260.93 EUR
7/20/20260.91 EUR
7/17/20260.89 EUR
7/16/20260.90 EUR
7/15/20260.90 EUR
7/14/20260.91 EUR
7/13/20260.90 EUR
7/10/20260.89 EUR
7/9/20260.89 EUR
7/8/20260.91 EUR
7/7/20260.90 EUR
7/6/20260.90 EUR
7/3/20260.90 EUR
7/2/20260.90 EUR
7/1/20260.91 EUR
6/30/20260.90 EUR
6/29/20260.90 EUR
6/26/20260.89 EUR
6/25/20260.89 EUR
6/24/20260.94 EUR
6/23/20260.89 EUR
6/22/20260.89 EUR
6/19/20260.89 EUR
6/18/20260.89 EUR
6/17/20260.93 EUR
6/16/20260.94 EUR
6/15/20260.93 EUR
6/12/20260.91 EUR
6/11/20260.92 EUR
6/10/20260.96 EUR
6/9/20260.94 EUR
6/8/20260.95 EUR
6/5/20260.93 EUR
6/4/20260.91 EUR
6/3/20260.92 EUR
6/2/20260.97 EUR
6/1/20261.02 EUR
5/29/20261.05 EUR
5/28/20261.06 EUR
5/27/20261.06 EUR
5/26/20261.13 EUR
5/25/20261.17 EUR
5/22/20261.03 EUR
5/21/20261.07 EUR
5/20/20261.07 EUR
5/19/20261.13 EUR
5/18/20260.93 EUR
5/15/20260.98 EUR
5/14/20260.93 EUR
5/13/20261.09 EUR
5/12/20261.30 EUR
5/11/20261.57 EUR
5/8/20261.10 EUR
5/7/20260.91 EUR
5/6/20260.74 EUR
5/5/20260.78 EUR
5/4/20260.80 EUR
4/30/20260.81 EUR
4/29/20260.80 EUR
4/28/20260.78 EUR
4/27/20260.79 EUR
4/24/20260.83 EUR
4/23/20260.83 EUR
4/22/20260.83 EUR
4/21/20260.87 EUR
4/20/20260.85 EUR
4/17/20260.86 EUR
4/16/20260.85 EUR
4/15/20260.85 EUR
4/14/20260.85 EUR
4/13/20260.85 EUR
4/10/20260.85 EUR
4/9/20260.84 EUR
4/8/20260.87 EUR
4/7/20260.85 EUR
4/2/20260.77 EUR
4/1/20260.80 EUR
3/31/20260.79 EUR
3/30/20260.80 EUR
3/27/20260.80 EUR
3/26/20260.84 EUR
3/25/20260.83 EUR
3/24/20260.85 EUR
3/23/20260.83 EUR
3/20/20260.82 EUR
3/19/20260.85 EUR
3/18/20260.85 EUR
3/17/20260.85 EUR
3/16/20260.85 EUR
3/13/20260.85 EUR
3/12/20260.86 EUR
3/11/20260.86 EUR
3/10/20260.87 EUR
3/9/20260.86 EUR
3/6/20260.89 EUR
3/5/20260.87 EUR
3/4/20260.87 EUR
3/3/20260.85 EUR
3/2/20260.93 EUR
2/27/20260.93 EUR
2/26/20260.94 EUR
2/25/20260.97 EUR
2/24/20260.96 EUR
2/23/20260.98 EUR
2/20/20260.99 EUR
2/19/20260.98 EUR
2/18/20260.92 EUR
2/17/20261.00 EUR
2/16/20261.01 EUR
2/13/20261.03 EUR
2/12/20261.02 EUR
2/11/20261.01 EUR
2/10/20261.04 EUR
2/9/20261.01 EUR
2/6/20261.02 EUR
2/5/20260.93 EUR
2/4/20260.92 EUR
2/3/20260.94 EUR
2/2/20260.96 EUR
1/30/20260.97 EUR
1/29/20261.04 EUR
1/28/20260.95 EUR
1/27/20261.04 EUR
1/26/20261.13 EUR
1/23/20260.88 EUR
1/22/20260.74 EUR
1/21/20260.74 EUR
1/20/20260.75 EUR
1/19/20260.73 EUR
1/16/20260.72 EUR
1/15/20260.73 EUR
1/14/20260.70 EUR
1/13/20260.73 EUR
1/12/20260.68 EUR
1/9/20260.58 EUR
1/8/20260.59 EUR
1/7/20260.59 EUR
1/6/20260.59 EUR
1/5/20260.60 EUR
1/2/20260.58 EUR
12/31/20250.60 EUR
12/30/20250.58 EUR
12/29/20250.59 EUR
12/24/20250.59 EUR
12/23/20250.59 EUR
12/22/20250.60 EUR
12/19/20250.61 EUR
12/18/20250.61 EUR
12/17/20250.61 EUR
12/16/20250.63 EUR
12/15/20250.58 EUR
12/12/20250.48 EUR
12/11/20250.48 EUR
12/10/20250.50 EUR
12/9/20250.49 EUR
12/8/20250.49 EUR
12/5/20250.48 EUR
12/4/20250.48 EUR
12/3/20250.48 EUR
12/2/20250.49 EUR
12/1/20250.50 EUR
11/28/20250.51 EUR
11/27/20250.50 EUR
11/26/20250.50 EUR
11/25/20250.50 EUR
11/24/20250.51 EUR
11/21/20250.51 EUR
11/20/20250.52 EUR
11/19/20250.52 EUR
11/18/20250.53 EUR
11/17/20250.51 EUR
11/14/20250.52 EUR
11/13/20250.51 EUR
11/12/20250.52 EUR
11/11/20250.54 EUR
11/10/20250.55 EUR
11/7/20250.54 EUR
11/6/20250.51 EUR
11/5/20250.54 EUR
11/4/20250.58 EUR
11/3/20250.61 EUR
10/31/20250.63 EUR
10/30/20250.63 EUR
10/29/20250.64 EUR
10/28/20250.65 EUR
10/27/20250.64 EUR
10/24/20250.65 EUR
10/23/20250.68 EUR
10/22/20250.68 EUR
10/21/20250.68 EUR
10/20/20250.68 EUR
10/17/20250.68 EUR
10/16/20250.69 EUR
10/15/20250.69 EUR
10/14/20250.68 EUR
10/13/20250.67 EUR
10/10/20250.68 EUR
10/9/20250.67 EUR
10/8/20250.70 EUR
10/7/20250.70 EUR
10/6/20250.65 EUR
10/3/20250.67 EUR
10/2/20250.69 EUR
10/1/20250.69 EUR
9/30/20250.69 EUR
9/29/20250.68 EUR
9/26/20250.61 EUR
9/25/20250.61 EUR
9/24/20250.61 EUR
9/23/20250.61 EUR
9/22/20250.60 EUR
9/19/20250.60 EUR
9/18/20250.61 EUR
9/17/20250.61 EUR
9/16/20250.61 EUR
9/15/20250.62 EUR
9/12/20250.61 EUR
9/11/20250.62 EUR
9/10/20250.60 EUR
9/9/20250.60 EUR
9/8/20250.60 EUR
9/5/20250.60 EUR
9/4/20250.60 EUR
9/3/20250.59 EUR
9/2/20250.59 EUR
9/1/20250.59 EUR
8/29/20250.60 EUR
8/28/20250.60 EUR
8/27/20250.60 EUR
8/26/20250.60 EUR
8/25/20250.60 EUR
8/22/20250.61 EUR
8/21/20250.60 EUR
8/20/20250.60 EUR
8/19/20250.60 EUR
8/18/20250.60 EUR
8/15/20250.61 EUR
8/14/20250.60 EUR
8/13/20250.60 EUR
8/12/20250.60 EUR
8/11/20250.61 EUR
Access this data via the Eulerpool API
Get Free API Key

Biosynex Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
31.20 M EUR
0.00 EUR
500,000.00 EUR
Jan 1, 2019
34.20 M EUR
1.20 M EUR
1.10 M EUR
Jan 1, 2020
153.90 M EUR
45.40 M EUR
31.40 M EUR
Jan 1, 2021
382.50 M EUR
140.60 M EUR
104.00 M EUR
Jan 1, 2022
196.60 M EUR
38.80 M EUR
15.60 M EUR
Jan 1, 2023
92.98 M EUR
-37.40 M EUR
-37.12 M EUR
Jan 1, 2024
101.17 M EUR
-36.33 M EUR
-43.33 M EUR
Jan 1, 2025 (e)
146.47 M EUR
5.97 M EUR
8.88 M EUR

Biosynex Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 8:12 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025e
1.001.001.001.004.009.0027.0030.0031.0034.00153.00382.00196.0092.00101.00146.00
––––300.00125.00200.0011.113.339.68350.00149.67-48.69-53.069.7844.55
5,700.005,700.00100.00100.0050.0055.5651.8550.0051.6155.8845.1053.9352.0453.2656.4456.44
57.0057.001.001.002.005.0014.0015.0016.0019.0069.00206.00102.0049.0057.0082.40
–––-1.00–––––1.0045.00140.0038.00-37.00-36.005.00
–––-100.00–––––2.9429.4136.6519.39-40.22-35.643.42
–––-1.00-1.00––––1.0031.00104.0015.00-37.00-43.008.00
––––––––––3,000.00235.48-85.58-346.6716.22-118.60
–––––––––––0.202.00––2.40
––––––––––––900.00–––
0.601.201.301.401.706.408.109.109.109.109.2011.1010.3012.6513.0213.02
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biosynex generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biosynex retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biosynex's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biosynex has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biosynex's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biosynex stock margins

The Biosynex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biosynex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biosynex.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
51.92 %
0.00 %
1.60 %
Jan 1, 2019
57.02 %
3.51 %
3.22 %
Jan 1, 2020
45.03 %
29.50 %
20.40 %
Jan 1, 2021
53.96 %
36.76 %
27.19 %
Jan 1, 2022
52.03 %
19.74 %
7.93 %
Jan 1, 2023
52.84 %
-40.23 %
-39.93 %
Jan 1, 2024
56.76 %
-35.91 %
-42.83 %
Jan 1, 2025 (e)
56.76 %
4.08 %
6.07 %

Biosynex Stock Revenue, EBIT, Earnings per Share

The Biosynex earnings per share therefore indicates how much revenue Biosynex has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
3.43 EUR
0.00 EUR
0.05 EUR
Jan 1, 2019
3.76 EUR
0.13 EUR
0.12 EUR
Jan 1, 2020
16.73 EUR
4.93 EUR
3.41 EUR
Jan 1, 2021
34.46 EUR
12.67 EUR
9.37 EUR
Jan 1, 2022
19.09 EUR
3.77 EUR
1.51 EUR
Jan 1, 2023
7.35 EUR
-2.96 EUR
-2.94 EUR
Jan 1, 2024
7.77 EUR
-2.79 EUR
-3.33 EUR
Jan 1, 2025 (e)
7.81 EUR
0.46 EUR
0.47 EUR

Biosynex business model & stock analysis

The company Biosynex SA was founded in 2005 in Strasbourg, France. The company is a manufacturer and distributor of diagnostic test kits used for the rapid and accurate diagnosis of various infectious diseases and other health conditions. Biosynex SA has established itself as a leading player in the global health market in recent years. The business model of Biosynex SA includes the design, manufacture, and distribution of various medical diagnostic tests that are capable of quickly and efficiently detecting pathogens and other health conditions. The company offers a wide range of medical test kits that can be used for the diagnosis of HIV/AIDS, hepatitis C, syphilis, rapid pregnancy tests, menopause, bleeding during pregnancy, vitamin D deficiency, and many other health conditions. The main focus of Biosynex SA is on developing test kits that are easy to use and provide accurate and reliable results. With its technological know-how and collaboration with leading experts in the field of medical diagnostics, Biosynex SA has taken a leading position in the development and marketing of medical diagnostic test kits. By collaborating with doctors, hospitals, and clinics globally, Biosynex SA has successfully expanded its business. Biosynex SA has various business areas specifically focused on the marketing and distribution of medical diagnostic tests. The most well-known areas include gynecology, infectious diseases, and pediatrics. Biosynex SA also has a strong presence in the global market, including Asia, Europe, Africa, and America. One of the most well-known products of Biosynex SA is the HIV self-test called Autotest VIH®, which is available in many European countries and North America. The test kit is CE marked and approved by leading health authorities such as the WHO and the EU. The product is an important tool in reducing the spread of HIV infections and allowing people to make a confidential diagnosis of HIV/AIDS in a private setting. In the field of gynecology, Biosynex SA offers various products such as the Unistick® pregnancy test, Unistick® ovulation test, and Unistick® menopause test kit. These products enable women to easily and efficiently diagnose pregnancy, ovulation, and menopause. The test kits are easy to use, can be used at home, and provide results within minutes. In summary, Biosynex SA has earned its leading position in the global market due to its focus on innovative technology and high-quality product range. The company has made a significant contribution to improving healthcare worldwide with its expertise and commitment to diagnosing health conditions. Biosynex SA will continue to expand its business in the future to support even more people worldwide and further improve the quality of healthcare.

Biosynex SWOT Analysis

Strengths

1. Established Reputation: Biosynex SA has built a strong reputation in the market for its reliable and high-quality medical diagnostics products.

2. Innovative Product Range: The company offers a diverse range of innovative diagnostic tests and kits, catering to various medical needs.

3. Strong Distribution Network: Biosynex has a wide distribution network, enabling it to reach healthcare professionals and consumers efficiently.

Weaknesses

1. Dependence on External Suppliers: Biosynex relies on external suppliers for certain components, posing a risk for supply chain disruptions.

2. Limited Global Presence: The company's market presence is primarily focused on Europe, limiting its exposure to potential growth opportunities in other regions.

3. Relatively Small Scale: Compared to larger competitors, Biosynex operates on a smaller scale, which may limit its ability to compete in terms of economies of scale.

Opportunities

1. Growing Demand for Diagnostic Tests: The increasing global focus on healthcare and disease prevention presents an opportunity for Biosynex to expand its customer base.

2. Emerging Markets: The company can explore and expand into emerging markets, leveraging its expertise and product portfolio.

3. Strategic Partnerships: Collaborating with other healthcare companies or research institutions can help Biosynex develop innovative solutions and expand its market reach.

Threats

1. Intense Competition: The medical diagnostics industry is highly competitive, with both established players and new entrants vying for market share.

2. Regulatory Challenges: Adhering to evolving regulatory standards and obtaining necessary approvals for products can pose challenges and impact time-to-market.

3. Economic Factors: Economic fluctuations, pricing pressures, and healthcare budget constraints can affect demand for Biosynex's products.

Biosynex Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biosynex historical P/E ratio, EBIT multiple, and P/S ratio

Biosynex annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biosynex shares outstanding

The number of shares of Biosynex was 13.02 M in 2025. This indicates how many shares Biosynex is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
9.10 M Stocks
Jan 1, 2019
9.10 M Stocks
Jan 1, 2020
9.20 M Stocks
Jan 1, 2021
11.10 M Stocks
Jan 1, 2022
10.30 M Stocks
Jan 1, 2023
12.65 M Stocks
Jan 1, 2024
13.02 M Stocks
Jan 1, 2025 (e)
13.02 M Stocks

Biosynex Dividend History

2 years of dividend payments

YearAnnual DividendYoY ChangePayments
20222.00EUR↑ 900.0%1×
20210.20EUR—1×

Biosynex dividend history and estimates

In 2025, Biosynex paid a dividend amounting to 2.40 EUR. Dividend means that Biosynex distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.20 EUR
0.00 EUR
Jan 1, 2022
2.00 EUR
0.00 EUR
Jan 1, 2025 (e)
0.00 EUR
2.40 EUR

Biosynex dividend payout ratio

In 2025, Biosynex had a payout ratio of 506.54%. The payout ratio indicates the percentage of the company's profits that Biosynex distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
66.86 %
Jan 1, 2019
66.86 %
Jan 1, 2020
66.86 %
Jan 1, 2021
2.14 %
Jan 1, 2022
131.58 %
Jan 1, 2023
66.86 %
Jan 1, 2024
66.86 %
Jan 1, 2025 (e)
506.54 %

Current Biosynex forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
12.85
Last Price
0.90
Currency
EUR
12M Return Potential
1,321.68 %
LTM Return
0 %

Biosynex shareholder structure

% Name
44.28177%
ALA Financière
ALA Financière
4.18209%
Abensur (Larry)
Abensur (Larry)
0.38870%
Sunny Asset Management
Sunny Asset Management
0.05071%
Abensur (Anita)
Abensur (Anita)
0.05071%
Abensur Family
Abensur Family
0.00000%
Mandarine Gestion
Mandarine Gestion

Biosynex Executives and Management Board

4 members · 0 % women

TP

Mr. Thierry Paper

Deputy Chief Executive Officer - Research and Business development, Administrator · since 2005

117,600.00 EUR

Management

LA

Mr. Larry Abensur

Chief Executive Officer, Director · since 2005

–
TL

Mr. Thomas Lamy

Deputy Chief Executive Officer, Director · since 2015

–

Board of Directors

EF

Mr. Elie Fraenckel

Director

–

Biosynex Supply Chain

Frequently asked questions about Biosynex

The business model of Biosynex SA revolves around the development, manufacturing, and distribution of rapid diagnostic tests (RDTs) for various medical conditions. Biosynex SA focuses on providing innovative and user-friendly diagnostic solutions that offer fast and reliable results. By leveraging cutting-edge technology and scientific expertise, Biosynex SA aims to improve the accessibility and efficiency of medical testing procedures. Their wide range of rapid diagnostic tests covers areas such as infectious diseases, women's health, gastroenterology, and cardiovascular conditions. Biosynex SA strives to contribute to better healthcare outcomes by offering accurate and time-sensitive diagnostic tools to healthcare professionals and patients alike.

Biosynex SA is primarily active in the healthcare industry.

The main competitors of Biosynex SA in the market include (insert competitors' names). The company operates in a highly competitive industry, and these competitors pose a challenge in terms of market share and product offerings. Biosynex SA has been consistently striving to differentiate itself through innovative products, strong marketing strategies, and extensive market presence. Despite the competitive landscape, Biosynex SA has successfully maintained its position and continues to expand its customer base through its commitment to quality, customer satisfaction, and continuous improvement.

Biosynex SA is a prominent company specializing in the field of medical diagnostics. Established in 2005, Biosynex has emerged as a leading player in the global healthcare industry. The company focuses on developing and manufacturing innovative diagnostic solutions, including rapid tests, for a wide range of medical conditions. With a strong commitment to research and development, Biosynex has achieved significant milestones in the diagnosis of various diseases, such as infectious diseases, women’s health, and cardiovascular disorders. Through strategic collaborations and a customer-centered approach, Biosynex SA continues to revolutionize the medical diagnostics landscape, ensuring accurate and efficient testing for patients worldwide.

Biosynex SA has achieved several significant milestones throughout its journey. The company has made substantial advancements in the field of diagnostic testing by developing innovative and reliable solutions. Biosynex SA has successfully initiated strategic partnerships and collaborations, expanding its global presence. Moreover, the company has gained regulatory approvals and certifications, ensuring the quality and safety of its products. With a commitment to continuous research and development, Biosynex SA has consistently introduced cutting-edge technologies to enhance healthcare outcomes. These milestones reflect Biosynex SA's dedication to providing breakthrough diagnostic solutions, positioning the company as a leader in the industry.

Biosynex SA is primarily present in various countries and regions worldwide. The company operates in several European countries, including France, Germany, Italy, Spain, and the United Kingdom. In addition, Biosynex SA has a presence in other regions such as North America, Africa, and Asia. With its diverse portfolio of innovative medical diagnostic solutions, Biosynex SA has expanded its market reach to serve healthcare professionals and patients globally.

Biosynex SA represents strong values and a clear corporate philosophy. The company's main focus is on providing innovative and reliable diagnostic solutions to improve patient care. Biosynex SA's values include integrity, excellence, and collaboration, aiming to deliver high-quality and accurate diagnostic tests. The company is committed to sustainability, ensuring that its operations are environmentally responsible. With a customer-centric approach, Biosynex SA strives to meet the evolving needs of healthcare professionals and patients. Through continuous innovation and a strong commitment to quality, Biosynex SA aims to make a positive impact in the field of medical diagnostics.

Analysts currently set an average price target of 12.85 EUR for the Biosynex stock (median: 12.85 EUR), implying +1,321.7 % versus the latest price. The consensus is based on 9 analyst ratings.

Biosynex Analyst Price Targets 2026

9 analysts currently rate the Biosynex stock: 8 recommend buying, 1 holding and 0 selling.

Biosynex Analyst Price Targets 2026

The Biosynex share (ALBIO.PA) is listed on 4 stock exchanges, including: Frankfurt (0DL.F), München (0DL.MU), Paris (ALBIO.PA).

Biosynex SA is a French company based in Strasbourg that specializes in the development, production, and marketing of rapid tests and other diagnostic solutions. The company was founded in 2005 and has since built up a wide portfolio of products that can be used in various areas such as healthcare, pregnancy, sexually transmitted diseases, and more. The business model of Biosynex SA is based on the manufacture and sale of rapid and easy diagnostic tests that can be used by medical professionals and end consumers. The company offers a wide range of diagnostic solutions, from pregnancy tests to tests for infectious diseases such as HIV, hepatitis B and C, as well as tests for cardiovascular diseases and drug abuse. An important sector of Biosynex SA is the healthcare sector. Here, the company offers various tests that can help detect diseases early and provide a quick diagnosis. These include tests for cholesterol, blood sugar, blood pressure, and other indicators of cardiovascular diseases. In addition, Biosynex SA also offers tests for body fluids such as urine and stool, which can help detect diseases such as urinary tract infections or colorectal cancer early. Another important area of Biosynex SA is the pregnancy sector. Here, the company offers fast and reliable tests that can usually be performed at home. Products in this category include pregnancy tests and ovulation tests, which can help women identify their fertile days and plan for pregnancy. Another important area of Biosynex SA is the sexually transmitted diseases sector. Here, the company offers tests for a variety of infectious diseases, including HIV, hepatitis B and C, chlamydia, and gonorrhea. These tests are easy to perform and can help detect and treat infections early. In addition to these important product categories, Biosynex SA also offers a range of diagnostic solutions that can be used in various medical fields. These include tests for drug abuse, respiratory diseases, anemia, and more. The business model of Biosynex SA is based on the production and sale of fast and reliable diagnostic tests that can be used in various medical fields. The company aims to expand its product range through continuous research and development and to create innovations that can help improve patients' lives and enhance the quality of medical care. The answer is: Biosynex SA is a French company specializing in the development and production of rapid tests and diagnostic solutions for various areas such as healthcare, pregnancy, sexually transmitted diseases, and more. They offer a wide range of tests for different medical needs and aim to improve patients' lives through research and development.

The revenue cannot currently be calculated for Biosynex.

The profit cannot currently be calculated for Biosynex.

The P/E ratio cannot be calculated for Biosynex at the moment.

The P/S cannot be calculated for Biosynex currently.

The Eulerpool Quality Score for Biosynex is 2/10.

The ISIN of Biosynex is FR0011005933. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biosynex is A1H8G1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biosynex is ALBIO.PA. The ticker symbol is used to trade Biosynex shares on the stock exchange.

The current dividend yield of Biosynex is 221.24 %.

Biosynex paid dividends every year for the past 0 years.

Biosynex is assigned to the 'Health' sector.

To receive the latest dividend of Biosynex from amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Biosynex are distributed in EUR.

All fundamentals and in-depth analysis of Biosynex

Our stock analysis for Biosynex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosynex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biosynex Stock
Biosynex Revenue→
Biosynex Stock
Biosynex Net Income→
Biosynex Stock
Biosynex P/E→
Biosynex Stock
Biosynex P/S→
Biosynex Stock
Biosynex EBIT→
Biosynex Stock
Biosynex Dividend→
Biosynex Stock
Biosynex Directors Dealings→
Biosynex Stock
Biosynex Stocks→
Biosynex Stock
Biosynex Market capitalization→
Biosynex Stock
Biosynex Debt→
Biosynex Stock
Biosynex Liabilities→
Biosynex Stock
Biosynex Equity→
Biosynex Stock
Biosynex AAQS→
Biosynex Stock
Biosynex Employees→
Biosynex Stock
Biosynex ROE→
Biosynex Stock
Biosynex ROA→
Biosynex Stock
Biosynex ROCE→
Biosynex Stock
Biosynex News→
Biosynex Stock
Biosynex Analyst Price Targets→

Health Stocks

BioteBioSyentBiotechnology AssetsBiostem TechnologiesBiotequeBiostaxBiotonBiostar PharmaceuticalsBioToxTech CoBiosino Bio-Technology and ScienceBiotronBiosergenAll Stocks A–Z →